Sarcoplasmic membrane muscle enzymes are released when damage of the muscle cell occurs or its membrane becomes defective. Serum muscle enzymes such as creatine kinase (CK), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), alanine amino-transferase (ALT), and aldolase are often elevated in DM and PM. Changes in the levels of serum enzymes depend on the form and severity of inflammatory muscle disease, and the applied therapy.
Creatine kinase (CK) catalyze the formation of adenosine triphosphate and the donation of a phosphate group to creatine, the combination of which is used as a high-energy storage molecule responsible for the energy transport in muscle fiber according to the so-called “creatine phosphate shuttle” [1]. The enzyme is a dimer consisting of two subu-nits, M (muscle) and B (brain), either with sulfhydryl groups present at the active sites of the enzyme. CK isoenzymes MM, MB, and BB are characteristic for skeletal muscle, myocardium, and brain respectively. In addition to differences in the activity ratios of enzymes and isoenzymes, the extent of CK increase also provides important diagnostic clues. CK is found in numerous organs such as skeletal muscles, myocardium, and brain in the ratio 10:2.5:1 respectively, but also in thyroid gland, kidney, and liver. In inflammatory muscle disease such as PM or DM, CK levels in sera could be elevated more than 50-fold higher than the normal upper limit [2]. CK-MM subtype is the most sensitive and the most specific enzyme marker for skeletal muscle damage. The CK-MB isoenzyme, which is usually a hallmark of acute myocardial injury, may also increase in DM/PM [3–5]. Recently, Hamilton and Sharpe [5] reported two cases of inflammatory muscle disease presenting as either PM or DM with raised serum levels of CK-MB isoenzyme and troponin T in the absence of acute myocardial damage. B units of CK can be abnormally produced by regenerating skeletal muscle when these patients are treated with corticosteroids [4, 6]. Inflammatory muscle diseases are an important cause for the increasement of cardiac injury markers such as CK-MB and troponins, which are raised in up to 75% of PM/DM patients [7]. CK is not a specific marker for myositis; however, in inflammatory muscle diseases, as well as after physical exercise or traumatic muscle damage, it is the most often elevated enzyme [1] (Table 30.1).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bohlmeyer TJ, Wu AH, Perryman MB. Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. Rheum Dis Clin North Am 1994; 20: 845–856.
Dalakas M. Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med 1991; 325(21): 1487–1498.
Hood D, Van Lente F, Estes M. Serum enzyme alterations in chronic muscle disease. Am J Clin Pathol 1991; 95: 401–407.
Kiely PD, Bruckner FE, Nisbet JA, et al. Serum skeletal troponin I in inflammatory muscle disease: relation to creatine kinase, CKMB and cardiac troponin I. Ann Rheum Dis 2000; 59: 750.
Hamilton JS, Sharpe PC. Two cases of inflammatory muscle disease presenting with raised serum concentrations of troponin T. J Clin Pathol 2005; 58: 1323–1324.
Bodor GS, Survant L, Voss EM, et al. Cardiac troponin T composition in normal and regenerating human skeletal muscle. Clin Chem 1997; 43: 476–484.
Prellwitz W, Hafner G, Rupprecht HJ, et al. Diagnostic and differential diagnostic value of troponins. Med Klin 1996; 91: 336–342.
Gunst JJ, Langlois MR, Delanghe JR, et al. Serum creatine kinase activity is not a reliable marker for muscle damage in conditions associated with low extracellular glutathione concentration. Clin Chem 1998; 44: 939–943.
Trask RV, Billadello JJ. Tissue specific distribution and developmental regulation of M and B creatine kinase mRNAs. Biochem Biophys Acta 1990; 1049: 182–188.
Panteghini M. Enzyme and muscle diseases. Curr Opin Rheum 1995; 7: 469–474.
Larca LJ, Coppola JT, Honig S. Creatine kinase MB isoenzyme in dermatomyositis: a non cardiac source. Ann Intern Med 1981; 94: 341–343.
Stonecipher MR, Callen J P, Jorizzo JL. The red face: dermatomyositis. Clin Dermatol 1993; 11: 261–273.
Kargen LJ, Aram S. Creatine kinase activity inhibitor in sera from patients with muscle disease. Arthritis Rheum 1987; 30: 213–217.
Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine kinase elevation: a poor prognostic sign. Am J Med 1986; 80: 329–332.
Montagna GL, Manzo C, Califanc E, et al. Absence of elevated creatine kinase in dermatomy-ositis does not exclude malignancy. Scand J Rheumatol 1988; 17: 73–74.
Gran JT, Myklebast G. Adult idiopathic polymyositis without elevation of creatine kinase: case report and review of the literature. Scand J Rheumatol 1993: 22: 94.
Rosalki SB. Serum enzymes in disease of skeletal muscle. Clin Lab Med 1989; 9: 767–781.
Pachman LM. Juvenile dermatomyositis. Pediatr Clin North Am 1995; 42: 1071–1098.
Vuori J, Rasi S, Takala T, et al. Dual-label time-resolved fluoroimmunoassay for simultaneous detection of myoglobin and carbonic anhydrase III in serum. Clin Chem 1991; 37: 2087–2092.
Kroll M, Otis J, Kagen L. Serum enzymes, myoglobin and muscle strength relationship in polymyositis and dermatomyositis. J Rheumatol 1986; 13: 349–355.
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
(2009). Muscle Enzymes. In: Dermatomyositis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79313-7_30
Download citation
DOI: https://doi.org/10.1007/978-3-540-79313-7_30
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-79312-0
Online ISBN: 978-3-540-79313-7
eBook Packages: MedicineMedicine (R0)